XBiotech lines up for a $76M IPO to fund its antibody R&D

Austin, TX's XBiotech has filed to make a $76 million Wall Street debut, plotting to bankroll a fleet of antibody therapies and an ambitious plan for a manufacturing and R&D campus. The company expects to offer 4 million shares at between $18 and $20 each, earmarking the majority of its proceeds to pay for Phase III trials on Xilonix, an interleukin-1 blocker with applications in multiple cancers. XBiotech plans to set aside $12 million of its haul to fund construction on a 46,000-square-foot operation in Austin, to which it is adding a commercial manufacturing facility. More

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.